Kalkine Media ASX Share Market News & Research
Watchlist Sign Up/Login
Kalkine Media ASX Share Market News & Research

Avacta Group Plc enters into a partnership and license agreement with LG Chem Life Sciences

1 min read | November 13, 2019 08:48 AM GMT | By Team Kalkine Media
Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Recent News

thumbnail

Gulf Shock and UK Slowdown Stir Market Jitters Across London Shares

thumbnail

CMC Markets and FTSE 100 Market Focus on Trading Platform Expansion

thumbnail

FTSE Market Watch: Ceasefire Calm Lifts Europe Outlook Shift

thumbnail

Just Group Shares Steady as UK Retirement Market Holds Focus

Make Kalkine Media
My Trusted Source

Google Source
  • Avacta Group Plc (AVCT) has released an update on the Affimer® therapeutics development partnership and license agreement.
  • The company to develop Affimer® therapeutics in various disease areas has collaborated with LG Chem Life Sciences and has also entered into a license agreement.
  • The company has effectively produced a large number of Affimer proteins that bind to the first drug target nominated by LG Chem Life Sciences, which has now expanded the collaboration by nominating the second and third drug targets.
  • The company is starting the discovery programmes for Affimer binders to those new targets.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

UK_Premium_Article

Sponsored Articles

1

Top 10 FTSE Listed Dividend Paying Stocks

2

KryptoByte and Archax Partner on Custody Framework for Energy-Derived...

3

Union Jack Oil (AIM:UJO) Unlocks Value with New Discoveries and Operat...

4

Union Jack Oil (LON:UJO) reports strong financials for 1H with £2MM ma...

5

A view of how UK’s lottery industry is embracing internet

Investing Ideas

Previous Next